

Human $\alpha 1$ type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by $\alpha 1\beta 1$ integrin

Akulapalli Sudhakar, ... , Dominic Cosgrove, Raghu Kalluri

J Clin Invest. 2020;**130**(1):552-552. <https://doi.org/10.1172/JCI135305>.

Retraction

Original citation: *J Clin Invest.* 2005;**115**(10):2801–2810. <https://doi.org/10.1172/JCI24813> Citation for this retraction: *J Clin Invest.* 2020;**130**(1):552. <https://doi.org/10.1172/JCI135305> The Office of Research Integrity recently notified the JCI of falsified data reported in this article. Therefore, the JCI is retracting the article.

Find the latest version:

<https://jci.me/135305/pdf>



Retraction

Human $\alpha 1$ type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by $\alpha 1\beta 1$ integrin

Akulapalli Sudhakar, Pia Nyberg, Venkateshwar G. Keshamouni, Arjuna P. Mannam, Jian Li, Hikaru Sugimoto, Dominic Cosgrove, and Raghu Kalluri

Original citation: *J Clin Invest*. 2005;115(10):2801–2810. <https://doi.org/10.1172/JCI24813>.

Citation for this retraction: *J Clin Invest*. 2020;130(1):552. <https://doi.org/10.1172/JCI135305>.

The Office of Research Integrity recently notified the *JCI* of falsified data reported in this article. Therefore, the *JCI* is retracting the article.

Corrigendum

X-linked macrocytic dyserythropoietic anemia in females with an *ALAS2* mutation

Vijay G. Sankaran, Jacob C. Ulirsch, Vassili Tchaikovskii, Leif S. Ludwig, Aoi Wakabayashi, Senkottuvelan Kadirvel, R. Coleman Lindsley, Rafael Bejar, Jiahai Shi, Scott B. Lovitch, David F. Bishop, and David P. Steensma

Original citation: *J Clin Invest*. 2015;125(4):1665–1669. <https://doi.org/10.1172/JCI78619>.

Citation for this corrigendum: *J Clin Invest*. 2020;130(1):552. <https://doi.org/10.1172/JCI132538>.

The amino acid substitution for the *ALAS2* mutation was incorrectly noted in the original article. The correct designation is *ALAS2* Y365H. The correct sentences and figure part are below.

Abstract:

We determined that this mutation (Y365H) impairs binding of the essential cofactor pyridoxal 5'-phosphate to *ALAS2*, resulting in destabilization of the enzyme and consequent loss of function.

Results and Discussion:

This A-to-G variant was found at position 55042086 on the X chromosome (hg19 coordinates), resulting in a coding change of Y365H in the *ALAS2* protein (Figure 1F and Supplemental Figure 1).

By modeling this novel *ALAS2* Y365H mutation in the structure of the *Rhodobacter capsulatus* homolog, we noted that Y365 fits within a hydrophobic core critical for binding the essential cofactor pyridoxal 5'-phosphate (PLP) (Figure 2A and ref. 16).

Together, these findings indicate that the Y365H mutation markedly impairs PLP binding, which may account for some or all of the substantially reduced stability of the *ALAS2* enzyme.

Figure 2 legend:

Severe LOF with the *ALAS2* Y365H mutation and lack of highly skewed X inactivation in female mutation carriers. (A) Model of *ALAS2* shows PLP highlighted in blue and the Y or H amino acid at position 365 highlighted in red.

The authors regret the errors.

